4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Haematologica, Vol 92, Issue 9, 1295-1296 doi:10.3324/haematol.10820
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mateos-Mazon, J.
Right arrow Articles by San Miguel, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mateos-Mazon, J.
Right arrow Articles by San Miguel, J. F.

Stem Cell Transplantation

Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation

Juan Mateos-Mazon, José-Antonio Pérez-Simón, Olga Lopez, Emiliano Hernández*, Jaime Etxebarria°, Jésus F. San Miguel

* Servicio de Hematología y Oftalmología, Hospital Clínico Universitario de Salamanca and
° Servicio de Oftalmología, Hospital de Cruces, Bilbao, Spain

Correspondence: J.A. Pérez-Simón, MD, PhD, Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Paseo de San Vicente s/n 37007, Salamanca, Spain. Fax: international 34-923-294624. Phone: international +34.923.291316. E-mail: pesimo{at}usal.es

We report on the use of bortezomib for the management of chronic graft versus host disease (cGVHD) among 8 multiple myeloma (MM) patients who relapsed after reduced-intensity conditioning (RIC) allogeneic transplantation. Five patients (62%) responded to bortezomib demonstrating anti-myeloma effect. Four patients had active cGVHD, including 3 patients with severe punctate keratopathy, at the time of bortezomib administration. All showed an improvement in their condition. This is the first report showing that bortezomib may be useful in the management of cGVHD and related ocular involvement.

Key words: cGVHD, multiple myeloma, bortezomib, allogeneic transplant.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
C. H. Weiss, G. R. S. Budinger, G. M. Mutlu, and M. Jain
Proteasomal Regulation of Pulmonary Fibrosis
Proceedings of the ATS, February 15, 2010; 7(1): 77 - 83.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Gahrton and B. Bjorkstrand
Allogeneic transplantation in multiple myeloma
Haematologica, September 1, 2008; 93(9): 1295 - 1300.
[Full Text] [PDF]